Tags

Type your tag names separated by a space and hit enter

Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: A Systematic Review and Meta-analysis.
Adv Nutr. 2020 07 01; 11(4):834-863.AN

Abstract

Fermented dairy foods (FDFs) and probiotics are promising tools for the prevention and management of cardiometabolic diseases (CMDs), respectively. The relation between the regular consumption of FDFs and CMD risk factors was assessed by prospective cohort studies (PCSs), and the effect of probiotic supplementation added into a dairy matrix on CMD parameters was evaluated by randomized controlled trials (RCTs). Moreover, the effects of probiotic supplementation added into a dairy matrix were compared with those administered in capsule/powder form. Twenty PCSs and 52 RCTs met the inclusion criteria for the systematic review and meta-analysis. In PCSs, fermented milk was associated with a 4% reduction in risk of stroke, ischemic heart disease, and cardiovascular mortality [RR (95% CI); 0.96 (0.94, 0.98)]; yogurt intake was associated with a risk reduction of 27% [RR (95% CI); 0.73 (0.70, 0.76)] for type 2 diabetes (T2D) and 20% [RR (95% CI); 0.80 (0.74, 0.87)] for metabolic syndrome development. In RCTs, probiotic supplementation added into dairy matrices produced a greater reduction in lipid biomarkers than when added into capsules/powder in hypercholesterolemic subjects, and probiotic supplementation by capsules/powder produced a greater reduction in T2D biomarkers than when added into dairy matrices in diabetic subjects. Both treatments (dairy matrix and capsules/powder) resulted in a significant reduction in anthropometric parameters in obese subjects. In summary, fermented milk consumption is associated with reduced cardiovascular risk, while yogurt intake is associated with a reduced risk of T2D and metabolic syndrome development in the general population. Furthermore, probiotic supplementation added into dairy matrices could be considered beneficial for lowering lipid concentrations and reducing anthropometric parameters. Additionally, probiotic capsule/powder supplementation could contribute to T2D management and reduce anthropometric parameters. However, these results should be interpreted with caution due to the heterogeneity of the studies and the different probiotic strains used in the studies. This trial is registered with PROSPERO (CRD42018091791) and the protocol can be accessed at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018091791.

Authors+Show Affiliations

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain.Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain.Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain. Universitat Rovira i Virgili Foundation, Universitat Rovira i Virgili, Reus and Tarragona, Spain.Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain.Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain. Hospital Universitari Sant Joan de Reus, Reus, Spain.Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain.Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

32277831

Citation

Companys, Judit, et al. "Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: a Systematic Review and Meta-analysis." Advances in Nutrition (Bethesda, Md.), vol. 11, no. 4, 2020, pp. 834-863.
Companys J, Pla-Pagà L, Calderón-Pérez L, et al. Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: A Systematic Review and Meta-analysis. Adv Nutr. 2020;11(4):834-863.
Companys, J., Pla-Pagà, L., Calderón-Pérez, L., Llauradó, E., Solà, R., Pedret, A., & Valls, R. M. (2020). Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: A Systematic Review and Meta-analysis. Advances in Nutrition (Bethesda, Md.), 11(4), 834-863. https://doi.org/10.1093/advances/nmaa030
Companys J, et al. Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: a Systematic Review and Meta-analysis. Adv Nutr. 2020 07 1;11(4):834-863. PubMed PMID: 32277831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: A Systematic Review and Meta-analysis. AU - Companys,Judit, AU - Pla-Pagà,Laura, AU - Calderón-Pérez,Lorena, AU - Llauradó,Elisabet, AU - Solà,Rosa, AU - Pedret,Anna, AU - Valls,Rosa M, PY - 2019/02/23/received PY - 2019/06/27/revised PY - 2020/02/28/accepted PY - 2020/4/12/pubmed PY - 2021/4/28/medline PY - 2020/4/12/entrez KW - cardiometabolic disease KW - fermented dairy KW - hypercholesterolemia KW - obesity KW - probiotics KW - type 2 diabetes SP - 834 EP - 863 JF - Advances in nutrition (Bethesda, Md.) JO - Adv Nutr VL - 11 IS - 4 N2 - Fermented dairy foods (FDFs) and probiotics are promising tools for the prevention and management of cardiometabolic diseases (CMDs), respectively. The relation between the regular consumption of FDFs and CMD risk factors was assessed by prospective cohort studies (PCSs), and the effect of probiotic supplementation added into a dairy matrix on CMD parameters was evaluated by randomized controlled trials (RCTs). Moreover, the effects of probiotic supplementation added into a dairy matrix were compared with those administered in capsule/powder form. Twenty PCSs and 52 RCTs met the inclusion criteria for the systematic review and meta-analysis. In PCSs, fermented milk was associated with a 4% reduction in risk of stroke, ischemic heart disease, and cardiovascular mortality [RR (95% CI); 0.96 (0.94, 0.98)]; yogurt intake was associated with a risk reduction of 27% [RR (95% CI); 0.73 (0.70, 0.76)] for type 2 diabetes (T2D) and 20% [RR (95% CI); 0.80 (0.74, 0.87)] for metabolic syndrome development. In RCTs, probiotic supplementation added into dairy matrices produced a greater reduction in lipid biomarkers than when added into capsules/powder in hypercholesterolemic subjects, and probiotic supplementation by capsules/powder produced a greater reduction in T2D biomarkers than when added into dairy matrices in diabetic subjects. Both treatments (dairy matrix and capsules/powder) resulted in a significant reduction in anthropometric parameters in obese subjects. In summary, fermented milk consumption is associated with reduced cardiovascular risk, while yogurt intake is associated with a reduced risk of T2D and metabolic syndrome development in the general population. Furthermore, probiotic supplementation added into dairy matrices could be considered beneficial for lowering lipid concentrations and reducing anthropometric parameters. Additionally, probiotic capsule/powder supplementation could contribute to T2D management and reduce anthropometric parameters. However, these results should be interpreted with caution due to the heterogeneity of the studies and the different probiotic strains used in the studies. This trial is registered with PROSPERO (CRD42018091791) and the protocol can be accessed at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018091791. SN - 2156-5376 UR - https://www.unboundmedicine.com/medline/citation/32277831/Fermented_Dairy_Products_Probiotic_Supplementation_and_Cardiometabolic_Diseases:_A_Systematic_Review_and_Meta_analysis_ L2 - https://academic.oup.com/advances/article-lookup/doi/10.1093/advances/nmaa030 DB - PRIME DP - Unbound Medicine ER -